The transaction is expected to strengthen Zydus’ presence in the US specialty oncology market by providing it with an established commercial platform focused on oncology supportive-care therapies.
Assertio’s portfolio includes ROLVEDON (eflapegrastim-xnst), a long-acting G-CSF biologic approved by the US Food and Drug Administration for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy.The company said that the deal is structured as a tender offer followed by a merger, subject to customary closing conditions, including the tender of a majority of Assertio’s outstanding common shares.
Zydus said the tender offer is expected to commence within five business days of signing the merger agreement.The transaction is expected to close in the 2026-27 financial year, subject to regulatory and other closing conditions.
Speaking on the development, Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited, said, “This transaction represents a strategic step in strengthening our specialty and oncology footprint in the US. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with our long-term strategy of building differentiated, durable specialty businesses globally.”
Also Read: Metropolis Healthcare Q4 profit zooms 2x on higher revenue, margins; declares dividend
Shares of Zydus Lifesciences Limited ended 1% higher at ₹940 on the NSE on Wednesday, ahead of the company’s announcement.
Also Read: Income Tax Department to step up tax recovery drive, target ₹2.57 lakh crore in pending dues
